Record Information
Version1.0
Creation Date2014-09-11 05:14:55 UTC
Update Date2026-03-26 18:31:18 UTC
Accession NumberCHEM003710
Identification
Common NameSpironolactone
ClassSmall Molecule
DescriptionA potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
Contaminant Sources
  • FooDB Chemicals
  • HMDB Contaminants - Urine
  • IARC Carcinogens Group 3
  • STOFF IDENT Compounds
  • T3DB toxins
  • ToxCast & Tox21 Chemicals
Contaminant Type
  • Diuretic
  • Drug
  • Ester
  • Ether
  • Metabolite
  • Mineralocorticoid Receptor Antagonist
  • Organic Compound
  • Synthetic Compound
Chemical Structure
Thumb
Synonyms
ValueSource
EspironolactonaChEBI
SpironolactonumChEBI
SpironolattoneChEBI
AldactoneKegg
Aldactone aHMDB
AquareductHMDB
Espironolactona mundogenHMDB
FrumikalHMDB
Generosan brand OF spironolactoneHMDB
Merck dura brand OF spironolactoneHMDB
Mundogen brand OF spironolactoneHMDB
Spiro l.u.t.HMDB
SpirobetaHMDB
SpirononeHMDB
Wörwag brand OF spironolactoneHMDB
CT-Arzneimittel brand OF spironolactoneHMDB
DuraspironHMDB
Ashbourne brand OF spironolactoneHMDB
Azupharma brand OF spironolactoneHMDB
FlumachHMDB
Pfizer brand OF spironolactoneHMDB
PractonHMDB
Spirono-isisHMDB
Betapharm brand OF spironolactoneHMDB
Spiro von CTHMDB
Alphapharm brand OF spironolactoneHMDB
Alpharma brand OF spironolactoneHMDB
Alter brand OF spironolactoneHMDB
Hormosan brand OF spironolactoneHMDB
JenaspironHMDB
Mayoly-spindler brand OF spironolactoneHMDB
Novo-spirotonHMDB
Roche brand OF spironolactoneHMDB
SpiractinHMDB
SpirogammaHMDB
SpirolactoneHMDB
Spirono isisHMDB
CT Arzneimittel brand OF spironolactoneHMDB
Cardel brand OF spironolactoneHMDB
Dexo brand OF spironolactoneHMDB
Espironolactona alterHMDB
Jenapharm brand OF spironolactoneHMDB
Novo spirotonHMDB
NovoSpirotonHMDB
Novopharm brand OF spironolactoneHMDB
Pharmafrid brand OF spironolactoneHMDB
Searle brand OF spironolactoneHMDB
SpirolangHMDB
SpirospareHMDB
VeroshpironHMDB
VerospironHMDB
VerospironeHMDB
Von CT, spiroHMDB
CT, Spiro vonHMDB
Chemical FormulaC24H32O4S
Average Molecular Mass416.573 g/mol
Monoisotopic Mass416.202 g/mol
CAS Registry Number52-01-7
IUPAC Name(1'S,2R,2'R,9'R,10'R,11'S,15'S)-9'-(acetylsulfanyl)-2',15'-dimethylspiro[oxolane-2,14'-tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan]-6'-ene-5,5'-dione
Traditional Namespironolactone
SMILES[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O
InChI IdentifierInChI=1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1
InChI KeyLXMSZDCAJNLERA-ZHYRCANASA-N
Chemical Taxonomy
Description belongs to the class of organic compounds known as spironolactones and derivatives. These are steroid lactones with a structure based on the spironolactone skeleton.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassSteroid lactones
Direct ParentSpironolactones and derivatives
Alternative Parents
Substituents
  • Spironolactone
  • 3-oxo-delta-4-steroid
  • 3-oxosteroid
  • Oxosteroid
  • Delta-4-steroid
  • Cyclohexenone
  • Gamma butyrolactone
  • Tetrahydrofuran
  • Carboxylic acid ester
  • Carbothioic s-ester
  • Cyclic ketone
  • Thiocarboxylic acid ester
  • Ketone
  • Lactone
  • Oxacycle
  • Carboxylic acid derivative
  • Organoheterocyclic compound
  • Sulfenyl compound
  • Thiocarboxylic acid or derivatives
  • Monocarboxylic acid or derivatives
  • Organic oxygen compound
  • Carbonyl group
  • Organic oxide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organosulfur compound
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External Descriptors
Biological Properties
StatusDetected and Not Quantified
OriginExogenous
Cellular Locations
  • Cytoplasm
  • Extracellular
  • Membrane
Biofluid LocationsNot Available
Tissue LocationsNot Available
Pathways
NameSMPDB LinkKEGG Link
Spironolactone PathwayNot AvailableNot Available
ApplicationsNot Available
Biological RolesNot Available
Chemical RolesNot Available
Physical Properties
StateSolid
AppearanceWhite powder.
Experimental Properties
PropertyValue
Melting Point134.5°C
Boiling PointNot Available
Solubility22 mg/L (at 25°C)
Predicted Properties
PropertyValueSource
Water Solubility0.002 g/LALOGPS
logP3.1ALOGPS
logP3.64ChemAxon
logS-5.3ALOGPS
pKa (Strongest Acidic)18.01ChemAxon
pKa (Strongest Basic)-4.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area60.44 ŲChemAxon
Rotatable Bond Count2ChemAxon
Refractivity113.5 m³·mol⁻¹ChemAxon
Polarizability46.03 ųChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Spectra
Spectra
Spectrum TypeDescriptionSplash KeyView
Predicted GC-MSPredicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positivesplash10-0h2u-0109000000-b5dcae38bb499eaabba7Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, PositiveNot AvailableSpectrum
Predicted GC-MSPredicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, PositiveNot AvailableSpectrum
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-014i-0000900000-5e2e1944e45fcef225d1Spectrum
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-014i-0000900000-406c100eed5b6cdc3286Spectrum
LC-MS/MSLC-MS/MS Spectrum - 15V, Positivesplash10-014i-0000900000-406c100eed5b6cdc3286Spectrum
LC-MS/MSLC-MS/MS Spectrum - 15V, Positivesplash10-014i-0000900000-5e2e1944e45fcef225d1Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Positivesplash10-00or-0009200000-27849e6f24a460d7ac90Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Positivesplash10-05mn-0129000000-5819587c9e746750f5c0Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Positivesplash10-01tl-0192000000-6a35fab760c0aa732723Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Negativesplash10-00xr-0009200000-defcf21ed513948675a3Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Negativesplash10-00di-1009000000-ebe97ba9dd52376b449fSpectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Negativesplash10-0006-9004000000-2eccefa334bd23b4cdc1Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Positivesplash10-014i-0002900000-f73d8e9df6c71e49d6ebSpectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Positivesplash10-0uy1-0569200000-db11732abcc12259a54dSpectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Positivesplash10-0ukc-4593000000-33eba50454259079f605Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Negativesplash10-014i-0001900000-329d630008c4558a5ec5Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Negativesplash10-00xr-7009500000-69af52e904d20a0c7b9bSpectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Negativesplash10-00di-8009000000-ba8deb5a673f3bd4868eSpectrum
MSMass Spectrum (Electron Ionization)splash10-0006-9836000000-9f600bd39c3b914c0b17Spectrum
Toxicity Profile
Route of ExposureFairly rapidly absorbed from the gastrointestinal tract. Food increases the bioavailability of unmetabolized spironolactone by almost 100%.
Mechanism of ToxicitySpironolactone is a specific pharmacologic antagonist of aldosterone, acting primarily through competitive binding of receptors at the aldosterone-dependent sodium-potassium exchange site in the distal convoluted renal tubule. Spironolactone causes increased amounts of sodium and water to be excreted, while potassium is retained. Spironolactone acts both as a diuretic and as an antihypertensive drug by this mechanism. It may be given alone or with other diuretic agents which act more proximally in the renal tubule. Aldosterone interacts with a cytoplasmic mineralocorticoid receptor to enhance the expression of the Na+, K+-ATPase and the Na+ channel involved in a Na+ K+ transport in the distal tubule . Spironolactone bind to this mineralcorticoid receptor, blocking the actions of aldosterone on gene expression. Aldosterone is a hormone; its primary function is to retain sodium and excrete potassium in the kidneys.
MetabolismRapidly and extensively metabolized. The metabolic pathway of spironolactone is complex and can be divided into two main routes: those in which the sulfur moiety is retained and those in which the sulfur moiety is removed by dethioacetylation. Spironolactone is transformed to a reactive metabolite that can inactivate adrenal and testicular cytochrome P450 enzymes. It also has anti-androgenic activity. Route of Elimination: The metabolites are excreted primarily in the urine and secondarily in bile. Half Life: 10 minutes
Toxicity ValuesThe oral LD50 of spironolactone is greater than 1,000 mg/kg in mice, rats, and rabbits.
Lethal DoseNot Available
Carcinogenicity (IARC Classification)3, not classifiable as to its carcinogenicity to humans. (4)
Uses/SourcesUsed primarily to treat low-renin hypertension, hypokalemia, and Conn's syndrome.
Minimum Risk LevelNot Available
Health EffectsNot Available
SymptomsAcute overdosage of spironolactone may be manifested by drowsiness, mental confusion, maculopapular or erythematous rash, nausea, vomiting, dizziness, or diarrhea. Spironolactone has been shown to be a tumorigen in chronic toxicity studies in rats.
TreatmentNot Available
Concentrations
Not Available
DrugBank IDDB00421
HMDB IDHMDB0014565
FooDB IDFDB006238
Phenol Explorer IDNot Available
KNApSAcK IDNot Available
BiGG IDNot Available
BioCyc IDNot Available
METLIN IDNot Available
PDB IDSNL
Wikipedia LinkSpironolactone
Chemspider ID5628
ChEBI ID9241
PubChem Compound ID5833
Kegg Compound IDC07310
YMDB IDNot Available
ECMDB IDNot Available
References
Synthesis Reference

Giuseppe Bernini, “Process for preparing micronized spironolactone.” U.S. Patent US4332721, issued July, 1975.

MSDSLink
General References
1. Wandelt-Freerksen E: [Aldactone in the treatment of sarcoidosis of the lungs (author's transl)]. Z Erkr Atmungsorgane. 1977 Jul;149(1):156-9.
2. Berardesca E, Gabba P, Ucci G, Borroni G, Rabbiosi G: Topical spironolactone inhibits dihydrotestosterone receptors in human sebaceous glands: an autoradiographic study in subjects with acne vulgaris. Int J Tissue React. 1988;10(2):115-9.
3. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999 Sep 2;341(10):709-17.
4. Simons K, Toomre D: Lipid rafts and signal transduction. Nat Rev Mol Cell Biol. 2000 Oct;1(1):31-9.
5. Watson AD: Thematic review series: systems biology approaches to metabolic and cardiovascular disorders. Lipidomics: a global approach to lipid analysis in biological systems. J Lipid Res. 2006 Oct;47(10):2101-11. Epub 2006 Aug 10.
6. Sethi JK, Vidal-Puig AJ: Thematic review series: adipocyte biology. Adipose tissue function and plasticity orchestrate nutritional adaptation. J Lipid Res. 2007 Jun;48(6):1253-62. Epub 2007 Mar 20.
7. Lingwood D, Simons K: Lipid rafts as a membrane-organizing principle. Science. 2010 Jan 1;327(5961):46-50. doi: 10.1126/science.1174621.
8. The lipid handbook with CD-ROM
9. https://www.ncbi.nlm.nih.gov/pubmed/?term=11300427